Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Evaluation of prevalence of enlarged mediastinal lymph nodes in lung cancer screening population with correlation with lung parenchymal findings and outcome.

Principal Investigator
Name
Edward Patz
Degrees
MD
Institution
Duke University Medical Center
Position Title
Professor of Radiology
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-427
Initial CDAS Request Approval
Jul 16, 2018
Title
Evaluation of prevalence of enlarged mediastinal lymph nodes in lung cancer screening population with correlation with lung parenchymal findings and outcome.
Summary
The prevalence of incidental enlarged mediastinal lymph nodes on lung cancer screening CT scans has been reported between 1-6%. Features used to be considered when reporting an abnormal lymph node is 1) size (short axis), 2) density, and 3) FDG activity if available. It has been well documented that metastatic lymph nodes are larger than benign lymph nodes. However, data on size, density, and location of mediastinal adenopathy in correlation with parenchymal findings and outcome in a screened population is lacking. There is also paucity of literature on the clinical importance of incidentally detected large lymph nodes in lung cancer screening population to provide an evidence based guideline for the optimal management of mediastinal adenopathy incidentally found in lung cancer screening population.
Aims

In this project we aim to assess the prevalence of mediastinal adenopathy in lung cancer screening population. We will also correlate the size, density, number and location of lymph nodes with lung parenchymal findings, and outcome to understand the best strategy to follow/manage mediastinal adenopathy in this population.

Collaborators

Hamid Chalian, M.D.
Holman P. McAdams, M.D., FACR
Youkyung Lee, M.D.
Fenghai Duan, PhD.
Edward F. Patz Jr., M.D.

Related Publications